NGAL is increased in serum and feces during active IBD and several studies have explored its role as a disease biomarker (de Bruyn et al. 2015; de Bruyn et al. 2014; Janas et al. 2014; Magro et al. 2017; Stallhofer et al. 2015; Yesil et al. 2013). The gene discussed is LCN2; the disease is inflammatory bowel disease.